Literature DB >> 28986450

STAP-2 protein promotes prostate cancer growth by enhancing epidermal growth factor receptor stabilization.

Yuichi Kitai1, Masashi Iwakami1, Kodai Saitoh1, Sumihito Togi1, Serina Isayama1, Yuichi Sekine1, Ryuta Muromoto1, Jun-Ichi Kashiwakura1, Akihiko Yoshimura2, Kenji Oritani3, Tadashi Matsuda4.   

Abstract

Signal-transducing adaptor family member-2 (STAP-2) is an adaptor protein that regulates various intracellular signaling pathways and promotes tumorigenesis in melanoma and breast cancer cells. However, the contribution of STAP-2 to the behavior of other types of cancer cells is unclear. Here, we show that STAP-2 promotes tumorigenesis of prostate cancer cells through up-regulation of EGF receptor (EGFR) signaling. Tumor growth of a prostate cancer cell line, DU145, was strongly decreased by STAP-2 knockdown. EGF-induced gene expression and phosphorylation of AKT, ERK, and STAT3 were significantly decreased in STAP-2-knockdown DU145 cells. Mechanistically, we found that STAP-2 interacted with EGFR and enhanced its stability by inhibiting c-CBL-mediated EGFR ubiquitination. Our results indicate that STAP-2 promotes prostate cancer progression via facilitating EGFR activation.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  STAT3; adaptor protein; c-CBL; prostate cancer; protein degradation; signal transduction

Mesh:

Substances:

Year:  2017        PMID: 28986450      PMCID: PMC5702677          DOI: 10.1074/jbc.M117.802884

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  Interactions of STAP-2 with Brk and STAT3 participate in cell growth of human breast cancer cells.

Authors:  Osamu Ikeda; Yuichi Sekine; Akihiro Mizushima; Misa Nakasuji; Yuto Miyasaka; Chikako Yamamoto; Ryuta Muromoto; Asuka Nanbo; Kenji Oritani; Akihiko Yoshimura; Tadashi Matsuda
Journal:  J Biol Chem       Date:  2010-10-07       Impact factor: 5.157

2.  Signal-transducing adaptor protein-2 controls the IgE-mediated, mast cell-mediated anaphylactic responses.

Authors:  Yuichi Sekine; Keigo Nishida; Satoru Yamasaki; Ryuta Muromoto; Shigeyuki Kon; Jun-Ichi Kashiwakura; Kodai Saitoh; Sumihito Togi; Akihiko Yoshimura; Kenji Oritani; Tadashi Matsuda
Journal:  J Immunol       Date:  2014-03-10       Impact factor: 5.422

3.  Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.

Authors:  C M Canil; M J Moore; E Winquist; T Baetz; M Pollak; K N Chi; S Berry; D S Ernst; L Douglas; M Brundage; B Fisher; A McKenna; L Seymour
Journal:  J Clin Oncol       Date:  2005-01-20       Impact factor: 44.544

4.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

Review 5.  Signal transducer and activator of transcription 3 regulation by novel binding partners.

Authors:  Tadashi Matsuda; Ryuta Muromoto; Yuichi Sekine; Sumihito Togi; Yuichi Kitai; Shigeyuki Kon; Kenji Oritani
Journal:  World J Biol Chem       Date:  2015-11-26

6.  Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts.

Authors:  Ingo K Mellinghoff; Chris Tran; Charles L Sawyers
Journal:  Cancer Res       Date:  2002-09-15       Impact factor: 12.701

7.  Molecular characterization of human prostate carcinoma cell lines.

Authors:  Adrie van Bokhoven; Marileila Varella-Garcia; Christopher Korch; Widya U Johannes; E Erin Smith; Heidi L Miller; Steven K Nordeen; Gary J Miller; M Scott Lucia
Journal:  Prostate       Date:  2003-11-01       Impact factor: 4.104

8.  Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype.

Authors:  D W Threadgill; A A Dlugosz; L A Hansen; T Tennenbaum; U Lichti; D Yee; C LaMantia; T Mourton; K Herrup; R C Harris
Journal:  Science       Date:  1995-07-14       Impact factor: 47.728

9.  The protein content of an adaptor protein, STAP-2 is controlled by E3 ubiquitin ligase Cbl.

Authors:  Yuichi Sekine; Chikako Yamamoto; Osamu Ikeda; Ryuta Muromoto; Asuka Nanbo; Kenji Oritani; Akihiko Yoshimura; Tadashi Matsuda
Journal:  Biochem Biophys Res Commun       Date:  2009-05-03       Impact factor: 3.575

10.  STAP-2/BKS, an adaptor/docking protein, modulates STAT3 activation in acute-phase response through its YXXQ motif.

Authors:  Mayu Minoguchi; Shigeru Minoguchi; Daisuke Aki; Akiko Joo; Tetsuya Yamamoto; Taro Yumioka; Tadashi Matsuda; Akihiko Yoshimura
Journal:  J Biol Chem       Date:  2003-01-22       Impact factor: 5.157

View more
  3 in total

1.  Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth.

Authors:  Nan Yao; Chen-Ran Wang; Ming-Qun Liu; Ying-Jie Li; Wei-Min Chen; Zheng-Qiu Li; Qi Qi; Jin-Jian Lu; Chun-Lin Fan; Min-Feng Chen; Ming Qi; Xiao-Bo Li; Jian Hong; Dong-Mei Zhang; Wen-Cai Ye
Journal:  Signal Transduct Target Ther       Date:  2020-10-09

Review 2.  Central Roles of STAT3-Mediated Signals in Onset and Development of Cancers: Tumorigenesis and Immunosurveillance.

Authors:  Shigeru Hashimoto; Ari Hashimoto; Ryuta Muromoto; Yuichi Kitai; Kenji Oritani; Tadashi Matsuda
Journal:  Cells       Date:  2022-08-22       Impact factor: 7.666

3.  Construction of a prognostic model with histone modification-related genes and identification of potential drugs in pancreatic cancer.

Authors:  Yuan Chen; Ruiyuan Xu; Rexiati Ruze; Jinshou Yang; Huanyu Wang; Jianlu Song; Lei You; Chengcheng Wang; Yupei Zhao
Journal:  Cancer Cell Int       Date:  2021-06-05       Impact factor: 5.722

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.